17/09/2026
Read below to read the research paper.
Kindly whats app for appointment , queries and send your reports on
09310138022
Dr Manu Bora
F, 10/4, Golf Course Rd, DLF Phase 1, Sector 27, Gurugram, Haryana 122001
Dr. Philippe Hernigou, a French orthopedic surgeon and pioneer in regenerative medicine, has demonstrated that injecting a patient's own bone marrow concentrate (BMAC) into subchondral bone lesions can prevent knee replacement in over 80% of knee OA patients for 10–15+ years. His studies show this technique regenerates subchondral bone, specifically aiding "bone on bone" cases.Key Findings on Dr. Hernigou’s Bone Marrow WorkLong-Term Results: A 15-year study showed that >85% of patients avoided knee replacement, and many preferred their treated knee over their previously replaced knee.Targeting Method: Hernigou specifically injects stem cells into the bone (intraosseous/subchondral) beneath the cartilage damage, not just into the joint fluid.Patient Selection: The best candidates often have significant subchondral bone edema (bone marrow lesions on MRI).Procedure: Bone marrow is harvested from the iliac crest (pelvis), concentrated, and injected to target the damaged areas.Alternatives: While some studies show BMAC is superior, other studies suggest it is a safe alternative to PRP or hyaluronic acid, providing significant improvement over 12 months.Dr. Hernigou's research, starting in the 1990s and continuing with 15-year follow-ups, serves as a cornerstone for using bone marrow stem cells to treat knee osteoarthritis.
